UroGen Releases Real-World Data Showing Safety of JELMYTO in Upper Tract Urothelial Carcinoma Patients

UroGen has announced the release of new real-world data (RWD) supporting the safety of JELMYTO administration via percutaneous nephrostomy tube for patients with upper tract urothelial carcinoma (UTUC). The multi-center study was based on retrospective data from 32 patients and was recently published in The British Journal of Urology International.

According to Kyle Rose, M.D., Urologic Oncology Fellow at Moffitt Cancer Center, “We found that antegrade administration of JELMYTO via a nephrostomy tube offered a low rate of ureteral stenosis and a favorable safety and tolerability profile overall. This study adds to the evidence that this form of administration is beneficial in many ways, including the ability to treat the elderly without the use of anesthesia, which can have negative cumulative effects when used repetitively.”

To read more, click here.

(Source: Business Wire, November 14^th, 2022)